Literature DB >> 35551466

Frequency and therapeutic strategy for patients with ovarian metastasis from gastric cancer.

Tsutomu Namikawa1, Akira Marui2, Keiichiro Yokota2, Yasuhiro Kawanishi2, Masaya Munekage2, Sunao Uemura2, Hiromichi Maeda2, Hiroyuki Kitagawa2, Michiya Kobayashi3, Kazuhiro Hanazaki2.   

Abstract

PURPOSE: This study aimed to analyze the clinicopathological features and treatment outcomes of ovarian metastasis from gastric cancer.
METHODS: This study included 155 female patients with unresectable advanced or recurrent gastric cancer at the Kochi Medical School between January 2007 and December 2021. A review of patients with ovarian metastasis was conducted, and their clinicopathological information and survival outcomes were compared with respect to ovarian metastasis.
RESULTS: Fifteen patients were diagnosed with ovarian metastasis from gastric cancer with a median age of 54 years (range: 30-87 years) and an incidence of 9.7%. The median age of patients who developed ovarian metastasis was significantly lower those without ovarian metastasis (54 years vs. 71 years, P = 0.014). The median survival time (MST) for 15 patients with unresectable advanced gastric cancer who developed ovarian metastasis was 21.4 months (range: 0.2-41.4 months). The MST for 15 patients who underwent surgical resection and systemic drug treatment including chemotherapy to ovarian metastasis was significantly higher than those who received systemic drug treatment alone (28.1 months vs. 10.0 months; P = 0.021).
CONCLUSION: Ovarian metastasis was found in 9.7% of female patients with unresectable advanced or recurrent gastric cancer and in younger patients than in those without ovarian metastasis. Multidisciplinary treatment, including surgical resection and systemic drug treatment for ovarian metastasis from gastric cancer, may benefit selected patients.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Gastric cancer; Krukenberg tumor; Ovarian metastasis; Survival

Mesh:

Year:  2022        PMID: 35551466     DOI: 10.1007/s00423-022-02543-3

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   2.895


  1 in total

1.  Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer.

Authors:  Li-Chun Lu; Yu-Yun Shao; Chih-Hung Hsu; Chiun Hsu; Wen-Fang Cheng; Yu-Lin Lin; Ann-Lii Cheng; Kun-Huei Yeh
Journal:  Anticancer Res       Date:  2012-08       Impact factor: 2.480

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.